Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Axsome Therapeutics Inc. investors can proceed with a proposed class action alleging the drugmaker misled them about a ...

Migraine is a common neurological syndrome that affects approximately 10–20% of the population. The pathophysiology of migraine is unclear. 5-hydroxytriptamine is a key mediator in the ...

The drug – a new dry powder intranasal formulation of the old migraine therapy dihydroergotamine mesylate (DHE) – showed a trend towards improvements in pain and other symptoms in the phase 3 ...

Carmel Valley’s Beate Illek represented California during Headache on the Hill, taking part in the Alliance for Headache ...

Existing treatments for endometriosis have changed little in the past 30 years and are often ineffective or have undesired ...

The American College of Physicians issues new guidance on the prevention of episodic migraine with pharmacologic treatment recommendations.

Overall, this guidance could help many migraine sufferers gain better control over their symptoms—and with fewer disruptions ...

A migraine attack is more than a headache. It can derail your entire day.

MINNEAPOLIS, Feb. 26, 2025 /PRNewswire/ -- For children and teens living with migraine, there may be a new preventive treatment ... Researchers found the drug zonisamide, which has been used ...

The American College of Physicians has released new guidelines for treating acute episodic migraines in nonpregnant adults in outpatient settings.